U.S. COMPANY FILING
AMGEN INC — Form 10-Q filed 2025-11-05
Filing text preview
Amgen's Q3 2025 total revenues rose 12% to $9.56B, net income up 14% to $3.22B. Nine-month revenues reached $26.89B, net income $6.38B. The company recorded $400M impairment in Q3 and $1.2B year-to-date for Otezla due to IRA Medicare price setting. BeOne investment fair value increased to $6.5B. Quarterly dividend maintained at $2.38 per share.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record